About Warren Hosseinion
Warren Hosseinion is a director at Veraxa Biotech AG.
Form D filings name Warren Hosseinion as an executive officer at Vesicor Therapeutics.
Warren Hosseinion reports to the SEC as a director, officer or major shareholder of 8 public companies, including Veraxa Biotech AG - Post de-SPAC (VRXA), Nutex Health (NUTX) and General Purpose Acquisition (GPAC).
Warren Hosseinion first appears on SEC filings in 2008.
Experience
This experience comes from SEC filings. The years are when the filings name Warren Hosseinion in the role, so the role may have started earlier or lasted longer.
VA
Veraxa Biotech AG
Director
2026 · Public company (VRXA)
VS
Veraxa Biotech AG - Post de-SPAC
Director
2026 · Public company (VRXA)
NI
Nutex Health Inc.
President and director
2019 – 2026 · Public company (NUTX)
GC
General Purpose Acquisition Corp.
Director
2025 · Public company (GPAC)
VI
Voyager Acquisition Corp./Cayman Islands
Director
2024 · Public company (VACH)
CI
Cardio Diagnostics Holdings, Inc.
Director
2022 – 2024 · Public company (CDIO)
AC
Altitude Acquisition Corp.
Director
2022 · Public company (ALTU)
AI
Astrana Health, Inc.
Co-Chief Executive Officer and director
2008 – 2018 · Public company (ASTH)
Key Colleagues at Startups
The people Warren Hosseinion works with at each company, as listed on that company's latest Form D.
Vesicor Therapeutics, Inc. · Form D, May 14, 2025